May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Human Aqueous Concentrations of Moxifloxacin and Gatifloxacin Following Two Multiple–Dose Topical Ocular Dosing Regimens With VIGAMOXTM and ZYMARTM
Author Affiliations & Notes
  • H.R. Katz
    Ophthalmology, Krieger Eye Institute, Baltimore, MD
  • S. Lane
    Associated Eye Care, Stillwater, MN
    Ophthalmology, University of Minnesota, Stillwater, MN
  • S. Masket
    Ophthalmology, Jules Stein Eye Institute, Los Angeles, CA
  • K. Sall
    Sall Eye Surgery Center, Bellflower, CA
  • S. Orr
    Alcon Research, Ltd., Fort Worth, TX
  • R. Faulkner
    Alcon Research, Ltd., Fort Worth, TX
  • S.M. Robertson
    Alcon Research, Ltd., Fort Worth, TX
  • D.C. Dahlin
    Alcon Research, Ltd., Fort Worth, TX
  • Footnotes
    Commercial Relationships  H.R. Katz, Alcon F, C; S. Lane, Alcon F; S. Masket, Alcon F; K. Sall, Alcon F; S. Orr, Alcon E; R. Faulkner, Alcon E; S.M. Robertson, Alcon E; D.C. Dahlin, Alcon E.
  • Footnotes
    Support  Alcon Laboratories Inc.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4907. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.R. Katz, S. Lane, S. Masket, K. Sall, S. Orr, R. Faulkner, S.M. Robertson, D.C. Dahlin; Human Aqueous Concentrations of Moxifloxacin and Gatifloxacin Following Two Multiple–Dose Topical Ocular Dosing Regimens With VIGAMOXTM and ZYMARTM . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4907.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the ocular absorption of moxifloxacin HCl ophthalmic solution, 0.5% (VIGAMOXTM) and gatifloxacin ophthalmic solution, 0.3% (ZYMARTM) by measuring the concentration of moxifloxacin (Moxi) and gatifloxacin (Gati) in the aqueous humor (AH) of patients undergoing cataract surgery following two different topical ocular dosing regimens. Methods: In an open–label, 2–arm, multiple–dose study, 120 cataract patients received either VIGAMOXTM or ZYMARTM according to one of two dosing regimens: operative eye treated with one drop every 15 minutes x 4 doses on day of surgery (regimen 1), or operative eye treated with one drop 4 times daily on the day prior to surgery, and one drop every 15 minutes x 4 doses on the day of surgery (regimen 2). Patients in both arms were randomized to one of 5 sampling times with the last dose administered 0.25, 0.50, 1, 2 or 3 hours prior to AH sampling. At the time of surgery, approximately 0.15 mL of AH was collected from the anterior chamber using a tuberculin syringe and stored frozen until analysis. AH samples were assayed using a validated HPLC–fluorescence method which simultaneously measured Moxi and Gati. Results: For regimens 1 and 2, Moxi AH Cmax was 3.1– and 2.3–fold higher than Gati, respectively. Moxi AH AUC0–3 was significantly (p<0.05) higher (>2–fold) than Gati for both regimens and exceeded the minimum bactericidal concentration (MBC) and mutant prevention concentration (MPC) for both S. epidermidis and S. aureus over the entire 3–hour sampling period. Conclusions: Findings showed that the ocular penetration of moxifloxacin is at least two–fold greater than for gatifloxacin with either regimen. These concentrations also demonstrate over an extended period of time that moxifloxacin exceeded the MIC, MBC, and MPC of pathogens that typically cause endophthalmitis.

Keywords: antibiotics/antifungals/antiparasitics • anterior chamber • cataract 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×